Fibrobiologics Common Stock Stock Market Value
| FBLG Stock | 0.34 0.01 3.03% |
| Symbol | FibroBiologics |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics Common. If investors know FibroBiologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroBiologics Common is measured differently than its book value, which is the value of FibroBiologics that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics Common's market value can be influenced by many factors that don't directly affect FibroBiologics Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
FibroBiologics Common 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to FibroBiologics Common's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of FibroBiologics Common.
| 10/24/2025 |
| 01/22/2026 |
If you would invest 0.00 in FibroBiologics Common on October 24, 2025 and sell it all today you would earn a total of 0.00 from holding FibroBiologics Common Stock or generate 0.0% return on investment in FibroBiologics Common over 90 days. FibroBiologics Common is related to or competes with Dare Bioscience, Aditxt, Ainos, Citius Pharmaceuticals, Moleculin Biotech, Apollomics, and SeaStar Medical. FibroBiologics Common is entity of United States More
FibroBiologics Common Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure FibroBiologics Common's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess FibroBiologics Common Stock upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 10.74 | |||
| Information Ratio | 0.0058 | |||
| Maximum Drawdown | 47.13 | |||
| Value At Risk | (12.82) | |||
| Potential Upside | 13.79 |
FibroBiologics Common Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for FibroBiologics Common's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as FibroBiologics Common's standard deviation. In reality, there are many statistical measures that can use FibroBiologics Common historical prices to predict the future FibroBiologics Common's volatility.| Risk Adjusted Performance | 0.0222 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.98) | |||
| Sortino Ratio | 0.0048 | |||
| Treynor Ratio | 0.0924 |
FibroBiologics Common January 22, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0222 | |||
| Market Risk Adjusted Performance | 0.1024 | |||
| Mean Deviation | 5.66 | |||
| Semi Deviation | 8.35 | |||
| Downside Deviation | 10.74 | |||
| Coefficient Of Variation | 5663.62 | |||
| Standard Deviation | 8.81 | |||
| Variance | 77.62 | |||
| Information Ratio | 0.0058 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.98) | |||
| Sortino Ratio | 0.0048 | |||
| Treynor Ratio | 0.0924 | |||
| Maximum Drawdown | 47.13 | |||
| Value At Risk | (12.82) | |||
| Potential Upside | 13.79 | |||
| Downside Variance | 115.33 | |||
| Semi Variance | 69.64 | |||
| Expected Short fall | (7.07) | |||
| Skewness | (0.40) | |||
| Kurtosis | 4.73 |
FibroBiologics Common Backtested Returns
At this point, FibroBiologics Common is out of control. FibroBiologics Common secures Sharpe Ratio (or Efficiency) of close to zero, which denotes the company had a close to zero % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for FibroBiologics Common Stock, which you can use to evaluate the volatility of the firm. Please confirm FibroBiologics Common's Mean Deviation of 5.66, downside deviation of 10.74, and Semi Deviation of 8.35 to check if the risk estimate we provide is consistent with the expected return of 0.0064%. The firm shows a Beta (market volatility) of 1.57, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, FibroBiologics Common will likely underperform. FibroBiologics Common right now shows a risk of 9.11%. Please confirm FibroBiologics Common treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside , to decide if FibroBiologics Common will be following its price patterns.
Auto-correlation | -0.4 |
Poor reverse predictability
FibroBiologics Common Stock has poor reverse predictability. Overlapping area represents the amount of predictability between FibroBiologics Common time series from 24th of October 2025 to 8th of December 2025 and 8th of December 2025 to 22nd of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of FibroBiologics Common price movement. The serial correlation of -0.4 indicates that just about 40.0% of current FibroBiologics Common price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.4 | |
| Spearman Rank Test | -0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Currently Active Assets on Macroaxis
When determining whether FibroBiologics Common is a strong investment it is important to analyze FibroBiologics Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics Common's future performance. For an informed investment choice regarding FibroBiologics Stock, refer to the following important reports:Check out FibroBiologics Common Correlation, FibroBiologics Common Volatility and FibroBiologics Common Alpha and Beta module to complement your research on FibroBiologics Common. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
FibroBiologics Common technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.